ARCHIVES

Study Would Try to Validate EGFR FISH as Predictive Marker for Benefit from Tarceva.

This article is from The Cancer Letter archive.

Vol. 33 No. 27 | July 13, 2007

Download PDF Visit The Full Archive

Related Articles

Promising Results For Glivec In CML Continue, FDA Grants Priority Review

April 27, 2001

DCT Board Approves Major Clinical Trials Changes, Regional Groups, New Effort In Surgical Oncology

October 10, 1980

Cancer Support Community Reports on Patient Experiences

October 24, 2014

Georgetown Sponsors Oncology Agent Development Meeting

March 21, 2003

Mammography Hazard In ACS-NCI Screening Charged

October 17, 1975

Continuing Resolution Expires March 27; NIH, NCI Hope For Budget Compromise

March 15, 2013